Program
Contraceptives, Oral, Combined
Also written as “Combined oral contraceptive [ethinyl estradiol/ norethisterone (EE/NET)]”, “Combined oral contraceptives (COC)” and “COC”.
Its studies are mostly in Bipolar Disorder, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 10 open or running | phase 1since Jun 6, 2007 | Jun 6, 2007 | none ahead |
| Merck KGaA, Darmstadt, Germany | 10 open or running | phase 1since Oct 8, 2025 | Oct 8, 2025 | none ahead |
| Viatris | 10 open or running | phase 1since Jan 29, 2020 | Jan 29, 2020 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 6, 2007First study: phase 1 study in Bipolar DisorderNew to GlaxoSmithKlineGlaxoSmithKline · NCT00483535 · 12 enrolled · United Kingdom
- Jan 29, 2020Viatris’s first study: phase 1 study in Healthy SubjectsNew to ViatrisViatris · NCT04255277 · 97 enrolled · France
- Oct 8, 2025Merck KGaA, Darmstadt, Germany’s first study: phase 1 study in HealthyNew to Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany · NCT07215806 · 20 enrolled · Germany
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07215806Healthy · Germany | 1 | Completed | Merck KGaA, Darmstadt, Germany | Nov 25, 2022 | 20 |
| NCT04255277Healthy Subjects · France | 1 | Completed | Viatris | Sep 14, 2021 | 97 |
| NCT00483535Bipolar Disorder · United Kingdom | 1 | Terminated | GlaxoSmithKline | Nov 16, 2007 | 12 |
How it is read
Names in the registry
- “Combined oral contraceptive [ethinyl estradiol/ norethisterone (EE/NET)]”, 1 entry
- “Combined oral contraceptives (COC)”, 1 entry
- “COC”, 1 entry
Conditions, from the studies’ own filings
- Bipolar Disorder, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.